Target intelligence / Profile preview

Iron(II) complexes (Labile Iron Pool) (LIP)

Target
LIP
Molecular classification
Metal ion, Redox-active catalyst, Other
01

Overview

Iron complexes involved in Fenton chemistry, primarily represented by the labile iron pool (LIP), consist of redox-active ferrous iron (Fe2+) that catalyzes the decomposition of hydrogen peroxide into highly reactive hydroxyl radicals [1]. This process, known as the Fenton reaction, is a central driver of oxidative stress and lipid peroxidation, particularly in the context of ferroptosis, a form of regulated cell death [2]. In healthy cells, iron is strictly sequestered by proteins like ferritin and transferrin; however, pathological accumulation of labile iron occurs in conditions such as hereditary hemochromatosis, thalassemia, and various neurodegenerative disorders [3]. Therapeutic intervention typically involves the use of iron chelators, such as deferoxamine, deferiprone, or deferasirox, which bind to these iron complexes to prevent their participation in radical-generating reactions [4]. Targeting these complexes is also a burgeoning strategy in oncology, where modulating iron levels can sensitize cancer cells to ferroptotic stimuli or inhibit tumor growth [2]. Beyond chelation, research into small-molecule inhibitors of the Fenton reaction aims to mitigate ischemia-reperfusion injury and chronic inflammation [1]. Monitoring these complexes often involves measuring labile plasma iron (LPI) to assess the risk of oxidative damage in patients with iron overload [4].

Other names
Ferrous ironFe2+Labile ironNon-heme ironRedox-active ironLabile plasma iron (LPI)
02

Mechanism of action

Iron chelation to prevent the catalytic formation of hydroxyl radicals via the Fenton reaction

03

Biological functions

Cell deathOxidative stress inductionRedox signalingLipid peroxidationOther
04

Disease associations

Neurodegenerative diseaseCancerCardiovascular diseaseInflammationHemochromatosisThalassemiaOther
05

Safety considerations

Iron deficiency anemiaAgranulocytosisRenal toxicityNeurotoxicityOff-target metal binding
06

Interacting drugs

Deferoxamine

4 more in the full profile.

07

Biomarkers

Serum ferritinLabile plasma iron (LPI)Malondialdehyde (MDA)Transferrin saturation

Beyond the preview

Go deeper on Iron(II) complexes (Labile Iron Pool) (LIP).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Iron(II) complexes (Labile Iron Pool) (LIP).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call